Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent

Journal of Clinical Microbiology

Volumn 45, Issue 10, 2007, Pages 3151-3154

  Rennie, Robert P ^a   Koeth, Laura ^b   Jones, Ronald N ^c,d   Fritsche, Thomas R ^c   Knapp, Cindy C ^e   Killian, Scott B ^e   Goldstein, Beth P ^f  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b Laboratory Specialists Inc   (United States)

^c JMI LABORATORIES   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Trek Diagnostic Systems   (United States)

^f Vicuron Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; DIMETHYL SULFOXIDE; GLYCOPEPTIDE; POLYSORBATE 80; SURFACTANT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHEMICAL MODIFICATION; CLINICAL LABORATORY; DILUTION; DRUG ACTIVITY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; SPECIES DIFFERENCE; STANDARD; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TECHNIQUE;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TEICOPLANIN;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 34247844143     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02411-06     Document Type: Article

References (12)

1. Anderegg, T. R., D. J. Biedenbach, and R. N. Jones. 2003. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity. J. Clin. Microbiol. 41:2795-2796.
2. Barry, A. L., L. B., Relier, G. H. Miller, J. A. Washington, F. D. Schoenknect, L. R. Peterson, R. S. Hare, and C. Knapp. 1992. Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides. J. Clin. Microbiol. 30:585-589.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. Approved standard M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Daly, J. S., R. A. Dodge, R. H. Glew, D. T. Soja, B. A. DeLuca, and S. Hebert. 1997. Effect of zinc concentration in Mueller-Hinton agar on susceptibility of Pseudomonas aeruginosa to imipenem. J. Clin. Microbiol. 35:1027-1029.
6. Fritsche, T. R., R. P. Rennie, B. P. Goldstein, and R. N. Jones. 2006. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms. J. Clin. Microbiol. 44:2988-2990.
7. Goldstein, B. P., R. N. Jones, T. R. Fritsche, and D. J. Biedenbach. 2006. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn. Microbiol. Infect. Dis. 54:83-87.
8. Jones, R. N., T. R. Fritsche, H. S. Sader, and B. P. Goldstein. 2005. Anti-microbial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. 17:593-600.
9. Jones, R. N., M. G. Stilwell, H. S. Sader, T. R. Fritsche, and B. P. Goldstein. 2006. Spectrum and potency of dalbavancin tested against 3,322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 54:149-153.
10. Lin, G., K. Credito, L. M. Ednie, and P. C. Appelbaum. 2005. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. 49:770-772.
11. Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48:137-143.
12. Streit, J. M., H. S. Sader, T. R. Fritsche, and R. N. Jones. 2005. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn. Microbiol. Infect. Dis. 53:307-310.